RA
Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
$40.45 -5.93% (-$2.55)
1M -18.00%
Market Cap $2.01B
P/E Ratio -
Div. Yield -
ROE 29.02%
Piotroski F-Score Weak
2/9Valuation
21 /100
Expensive P/S 100.32x
P/B 4.74x
P/E N/A
Growth
100 /100
Growing Book val. growth 191.81%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 100.00%
FCF margin 485.75%
Net margin 685.80%
Quality
1 /100
Poor ROIC 35.45%
Asset turnover 0.04x
ROE 29.02%
Debt
100 /100
Low Debt/Equity 0.02x
Current ratio 15.72x
Int. coverage N/A
Stability
31 /100
Unstable Beta 1.03x
Profitable years 0
EPS volatility 169.43%
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre RAPP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Abraham N. Ceesay
Employees
84
Headquarters
Boston
Evenimente viitoare
05 NOV.
Earnings
Upcoming earnings report